Current trends and future implications in sepsis treatment

Turkish Journal of Medical Sciences

Volumn 38, Issue 6, 2008, Pages 501-510

  Yildiz, Bariş Doǧu ^a   Yorganci, Kaya ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Anticoagulants; Glucocorticoids; Immunoglobulins; Insulin; Sepsis; Toll like receptors

Indexed keywords

ANTIGENS; HORMONES; INSULIN; INTERFERONS;

ANTICOAGULANTS; GLUCOCORTICOIDS; IMMUNOGLOBULINS; SEPSIS; TOLL-LIKE RECEPTORS;

BINDING SITES;

6 [N (2 CHLORO 4 FLUOROPHENYL)SULFAMOYL] 1 CYCLOHEXENE 1 CARBOXYLIC ACID ETHYL ESTER; ACTIVATED PROTEIN C; CORTICOSTEROID; DEXAMETHASONE; DROTRECOGIN; ERITORAN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; INDUCIBLE NITRIC OXIDE SYNTHASE; TOLL LIKE RECEPTOR;

ADRENAL INSUFFICIENCY; ANTIINFLAMMATORY ACTIVITY; APACHE; BACTERIAL MENINGITIS; CONTINUOUS INFUSION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INNATE IMMUNITY; MEAN ARTERIAL PRESSURE; NONHUMAN; PNEUMOCYSTIS PNEUMONIA; RESUSCITATION; REVIEW; SEPSIS; SEPTIC SHOCK; SINGLE DRUG DOSE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; SYSTEMIC VASCULAR RESISTANCE; TREATMENT INDICATION; TYPHOID FEVER;

EID: 56849097887     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Lever A, Mackenzie I. Sepsis: definition, epidemiology, and diagnosis. BMJ 2007; 335: 879-83.
2. Angus DC, Wax RS. Epidemiology of sepsis: an update. Crit Care Med 2001; 29: 109-16.
3. Jenkins I. Evidence-based sepsis therapy: a hospitalist perspective. J Hosp Med 2006; 1: 285-95.
4. Howell G, Tisherman SA. Management of sepsis. Surg Clin N Am 2006; 86: 1523-39.
5. Deans KJ, Haley M, Natanson C, Eichacker PQ, Minneci PC. Novel therapies for sepsis: a review. J Trauma 2005 Apr; 58(4): 867-74.
6. Perla D, Marmorston J. Suprarenal cortical hormone and salt in the treatment of pneumonia and other severe infections. Endocrinology 1940; 27: 367-37.
7. Annane D, Sébille V, Troché G, Raphaël JC, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000; 283: 1038-45.
8. Annane D, Bellissant E, Sébille V, Lesieur O, Mathieu B, Raphaël JC et al. Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve. Br J Clin Pharmacol 1998; 46: 589-97.
9. Di Rosa M, Radomski M, Carnuccio R, Moncada S. Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages. Biochem Biophys Res Commun 1990; 172: 1246-52.
10. Radomski MW, Palmer RM, Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci USA 1990; 87: 10043-7.
11. Barber AE, Coyle SM, Marano MA, Fischer E, Calvano SE, Fong Y et al. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol 1993; 150: 1999-2006.
12. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for treating severe sepsis and septic shock. Cochrane Database Syst Rev 2004; (1): CD002243. Review.
13. Minneci PC, Deans KJ, Banks SM, Eichacker PQ, Natanson C. Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 2004; 141: 47-56.
14. Cicarelli DD, Benseñor FE, Vieira JE. Effects of single dose of dexamethasone on patients with systemic inflammatory response. Sao Paulo Med J. 2006 Mar 2; 124(2): 90-5.
15. Luce JM. Physicians should administer low-dose corticosteroids selectively to septic patients until an ongoing trial is completed. Ann Intern Med 2004 Jul 6; 141(1): 70-2.
16. Aukrust P, Frøland SS, Liabakk NB, Müller F, Nordøy I, Haug C et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994 Oct 1; 84(7): 2136-43.
17. Lindquist L, Lundbergh P, Maasing R. Pepsin-treated human gamma globulin in bacterial infections. A randomized study in patients with septicaemia and pneumonia. Vox Sang 1981 May; 40(5): 329-37.
18. Jones RJ, Roe EA, Gupta JL. Controlled trial of Pseudomonas immunoglobulin and vaccine in burn patients. Lancet 1980 Dec 13; 2(8207): 1263-5.
19. Alejandria MM, Lansang MA, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev 2002; CD001090.
20. Pildal J, Gotzsche PC. Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clin Infect Dis 2004; 39:38-46.
21. Laupland K, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med 2007; 35: 2686-92.
22. Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 2007; 35: 2677-85.
23. Werdan K, Pilz G, Bujdoso O, Fraunberger P, Neeser G, Schmieder RE et al. Score-based immunoglobulin G therapy of patients with sepsis: The SBITS study. Crit Care Med 2007; 35: 2693-701.
24. Fourrier F. Recombinant human activated protein C in the treatment of severe sepsis: an evidence-based review. Crit Care Med 2004; 32[Suppl.]: S534-S541.
25. Opal SM, Esmon CT. Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care 2003; 7: 23-38.
26. Gando S, Kameue T, Nanzaki S, Nakanishi Y. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost 1996; 75: 224-8.
27. Westendorp RG, Hottenga JJ, Slagboom PE. Variation in plasminogen activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 1999; 354: 561-3.
28. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-45.
29. Chavakis T, Pixley RA, Isordia-Salas I, Colman RW, Preissner KT. J Biol Chem 2002 Sep 6; 277(36): 32677-82. Epub 2002 Jun 24.
30. Renckens R, Roelofs JJTH, Horst SAJ, Veer CVT, Havik SV, Florquin S et al. Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice. J Immunol, 2005; 175: 6764-71.
31. Zeerleder S, Schroeder V, Hack CE, Kohler HP, Wuillemin WA. TAFI and PAI-1 levels in human sepsis. Thromb Res 2006; 118: 205-12.
32. Ravindranath TM, Goto M, Iqbal O, Florian-Kujawski M, Hoppensteadt D, Hammadeh R et al. Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsis. Clin Appl Thromb Hemost 2007 Oct; 13(4): 362-8.
33. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis. A randomized controlled trial. JAMA. 2003 Jul 9; 290(2): 238-47. OPTIMIST Trial Study Group.
34. LaRosa SP, Opal SM. Tissue factor pathway inhibitor and antithrombin trial results. Crit Care Clin 2005; 21: 433-48.
35. Eisele B, Lamy M. Clinical experience with antithrombin III concentrates in critically ill patients with sepsis and multiple organ failure. Semin Thromb Hemost 1998, 24: 71-80.
36. Jordan RE, Kilpatrick J, Nelson RM. Heparin promotes the inactivation of antithrombin by elastase. Science 1987; 237: 777-9.
37. Niessen RW, Lamping RJ, Jansen PM, Prins MH, Peters M, Taylor FB et al. Antithrombin acts as a negative acute phase protein as established with studies on HepG2 cells and in baboons. Thromb Haemost 1997; 78: 1088-92.
38. Reinisch C, Kaneider N, Rabensteiner A, Dunzendorfer B, Röuisch J, Weidermann CJ. Antithrombin reduces expression of IL-6 and TF, inhibits activation of the transcription factor NF- in lipopolysaccharide stimulated monocytes and endothelial cells. Specific deactivation of monocyte and lymphocyte migration by ATIII concentrate. Intensive Care Med 2000; 26: S302, A341.
39. Hoffmann JN, Vollmar B, Inthorn D, Schildberg FW, Menger MD. Antithrombin reduces leukocyte adhesion during chronic endotoxemia by modulation of the cyclooxygenase pathway. Am J Cell Physiol 2000; 279: C98-C107.
40. Taylor FB, Emerson TE, Jordan R, Chang AK, Blick KE. Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock 1988; 26: 227-35.
41. Rublee D, Opal SM, Schramm W, Keinecke H-O, Knaub S. Quality of life effects of AT III in sepsis survivors: results from the Kybersept trial. Crit Care 2002; 6: 249-56.
42. Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast J, Briegel J. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med 2006; 34: 285-92.
43. Esmon CTJ. The roles of protein C and thrombomodulin in the regulation of blood coagulation. Biol Chem 1989 Mar 25; 264(9): 4743-6.
44. Bajzar L, Nesheim M, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996; 88: 2093-100.
45. Alsfasser G, Warshaw AL, Thayer SP, Antoniu B, Laposata M, Lewandrowski KB. Decreased inflammation and improved survival with recombinant human activated protein C treatment in experimental acute pancreatitis. Arch Surg 2006 Jul; 141(7): 670-6.
46. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001; 276: 11199-203.
47. Fisher CJ, Yan SB. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med 2000; 28: S49-S56.
48. Liaw PCY, Ferrell GL, Loeb M, Foley R, Weitz JI, Esmon CT. Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood 2001; 98: 445a.
49. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A et al.; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
50. Bernard GR, Macias WL, Joyce DE, Williams MD, Bailey J, Vincent JL. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Crit Care 2003; 7(2): 155-63.
51. Haley M, Cui X, Minneci PC, Deans KJ, Natanson C, Eichacker PQ. Activated protein C in sepsis: emerging insights regarding its mechanism of action and clinical effectiveness. Curr Opin Infect Dis 2004 Jun; 17(3): 205-11. Review.
52. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL et al.; Administration of Drotrecogin Alfa (activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353: 1332-41.
53. Laterre PF, Abraham E, Janes JM, Trzaskoma BL, Correll NL, Booth FV. ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: One-year safety and efficacy evaluation.Crit Care Med 2007; 35: 1457-63.
54. Martí-Carvajal A, Salanti G, Cardona AF. Human recombinant activated protein C for severe sepsis (Review). Cochrane Database of Systematic Reviews 2007, Issue 3.
55. Garlund B. Activated protein C (Xigris©) treatment in sepsis: a drug in trouble. Acta Anaesthesiol Scand 2006 Sep; 50(8): 907-10.
56. Han Y, Englert JA, Yang R, Delude RL, Fink MP. Ethyl pyruvate inhibits nuclear factor-kappaB-dependent signaling by directly targeting p65. J Pharmacol Exp Ther 2005 Mar; 312(3): 1097-105.
57. Sappington PL, Cruz RJ Jr, Harada T, Yang R, Han Y, Englert JA et al. The ethyl pyruvate analogues, diethyl oxaloproprionate, 2-acetamidoacrylate, and methyl-2-acetamidoacrylate, exhibit antiinflammatory properties in vivo and/or in vitro. Biochem Pharmacol 2005 Nov 25; 70(11): 1579-92.
58. Venkataraman R, Kellum JA, Song M, Fink MP. Resuscitation with Ringer's ethyl pyruvate solution prolongs survival and modulates plasma cytokine and nitrite/nitrate concentrations in a rat model of lipopolysaccharide induced shock. Shock 2002; 18(6): 507-12.
59. Ulloa L, Ochani M, Yang H, Tanovic M, Halperin D, Yang R et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A 2002 Sep 17; 99(19): 12351-6.
60. Wagman AS, Johnson KW, Bussiere DE. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Curr Pharm Des 2004; 10(10): 1105-37. Review.
61. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement for glycogen synthase kinase-3b in cell survival and NF-kB activation. Nature 2000 Jul 6; 406(6791): 86-90.
62. Evenson AR, Fareed MU, Menconi MJ, Mitchell JC, Hasselgren PO. GSK-3b inhibitors reduce protein degradation in muscles from septic rats and in dexamethasone treated myotubes. Int J Biochem Cell Biol 2005 Oct; 37(10): 2226-38.
63. Bi X, Baudry M, Liu J, Yao Y, Fu L, Brucher F et al. Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia. J Biol Chem 2004 Nov 12; 279(46): 48238-45.
64. Dichtl W, Dulak J, Frick M, Alber HF, Schwarzacher SP, Ares MP et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003 Jan 1; 23(1): 58-63.
65. Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997 Nov 1; 30(5): 1212-7.
66. Yoshida M, Sawada T, Ishii H, Gerszten RE, Rosenzweig A, Gimbrone MA Jr et al. Hmg-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism. Arterioscler Thromb Vasc Biol 2001 Jul; 21(7): 1165-71.
67. Kallen J, Welzenbach K, Ramage P, Geyl D, Kriwacki R, Legge G. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J Mol Biol 1999 Sep 10; 292(1): 1-9.
68. Merx MW, Liehn EA, Janssens U, Lütticken R, Schrader J, Hanrath P et al. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 2004 Jun 1; 109(21): 2560-5.
69. Steiner S, Speidl WS, Pleiner J, Seidinger D, Zorn G, Kaun C et al. Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 2005; 111: 1841-6.
70. Niessner A, Steiner S, Speidl WS, Pleiner J, Seidinger D, Maurer G et al. Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis 2006 Dec; 189(2): 408-13.
71. Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004 Aug 17; 110(7): 880-5.
72. Thomsen RW, Hundborg HH, Johnsen SP, Pedersen L, Sørensen HT, Schønheyder HC et al. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med 2006 Apr; 34(4): 1080-6.
73. Fernandez R, De Pedro VJ, Artigas A. Statin therapy prior to ICU admission: protection against infection or a severity marker? Intensive Care Med 2006 Jan; 32(1): 160-4.
74. Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 2006 Feb 4; 367(9508): 413-8.
75. Janeway CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216.
76. Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature 2006; 442: 39-44.
77. Moynagh PN. TLR signalling and activation of IRFs: revisiting old friends from the NF- B pathway. Trends Immunol 2005; 26: 469-76.
78. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4: 499-511.
79. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007; 13: 552-9.
80. Hawkins LD, Christ WJ, Rossignol DP. Inhibition of endotoxin response by synthetic TLR4 antagonists. Curr Top Med Chem 2004; 4: 1147-71.
81. Mullarkey M, Rose JR, Bristol J, Kawata T, Kimura A, Kobayashi S et al. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther 2003; 304: 1093-102.
82. Lynn M, Rossignol DP, Wheeler JL, Kao RJ, Perdomo CA, Noveck R et al. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis 2003; 187: 631-9.